Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,).

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Abstract Text:

Hyun Ho Jung,Hwa Jung Yi,Seung Kyu Lee,Ju Yeon Lee,Hoi Jong Jung,Sung Tae Yang,Young-Jae Eu,Sin-Hyeog Im,Jae Il Kim,Hyun Ho Jung,Hwa Jung Yi,Seung Kyu Lee,Ju Yeon Lee,Hoi Jong Jung,Sung Tae Yang,Young-Jae Eu,Sin-Hyeog Im,Jae Il Kim,

Myasthenia gravis (MG) and its animal model, experimental MG (EAMG), are autoimmune disorders in which major pathogenic antibodies are directed against the main immunogenic region (MIR) of the nicotinic acetylcholine receptor (nAChR). In an earlier attempt to develop peptide mimotopes capable of preventing the anti-MIR-mediated pathogenicity, the peptide Pep.1 was initially identified from phage display, and subsequently, Cyclic extended Pep.1 (Cyc.ext.Pep.1), which incorporates eight additional residues into the Pep.1 sequence and has an affinity for the anti-MIR antibody mAb198 3 orders of magnitude greater than that of Pep.1, was developed. In an animal model, Pep.1 shows no ability to inhibit mAb198-induced EAMG, whereas Cyc.ext.Pep.1 successfully blocks anti-MIR antibody 198 (mAb198)-induced EAMG. Our aim in this study was to identify the structural characteristics related to the different affinities for mAb198 of Pep.1 and Cyc.ext.Pep.1 using NMR spectroscopy and alanine scanning analysis. The NMR structural analysis revealed that Pep.1 is very flexible in solution, whereas Cyc.ext.Pep.1 is highly rigid within a region containing several turn structures. Interestingly, TRNOE experiments revealed that mAb198-bound Pep.1, particularly in the region between Asn7 and Glu11, shows significant structural similarity to the region between Asn10 and Glu14 of Cyc.ext.Pep.1, which is critical for interaction with mAb198. We therefore conclude the higher affinity of Cyc.ext.Pep.1 for mAb198 reflects the fact that incorporation of additional residues producing a single disulfide bond endows Pep.1 with a conformational rigidity that mimics the structure of mAb198-bound Pep.1. Furthermore, our results suggest that cyclic extended peptides could be utilized generally as useful tools to optimize the affinity of phage library-derived peptide antigens.

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Publishing Authors By Initials

HH Jung,HJ Yi,SK Lee,JY Lee,HJ Jung,ST Yang,YJ Eu,SH Im,JI Kim,HH Jung,HJ Yi,SK Lee,JY Lee,HJ Jung,ST Yang,YJ Eu,SH Im,JI Kim,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Biochemistry

VOLUME: 46

Page Numbers: 14987-95

Journal Abbreviation: Biochemistry

ISSN: 0006-2960

DAY: 1

MONTH: 12

YEAR: 2007

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370623

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis(,).

AFFILIATION: Department of Life Sciences, Research Center for Biomolecular Nanotechnology, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Biochemistry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Structural analysis of immunotherapeutic peptides for autoimmune myasthenia gravis, Related Publications

• Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.
• Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas.
• Advanced capabilities for future light sources.
• Aging of the population and the subsequent increase in the mistreatment of the elderly in Korea.
• Alkali-catalyzed beta-elimination of periodate-oxidized glycans: a novel method of chemical deglycosylation of mucin gene products in paraffin embedded sections.
• Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence.
• Basic fibroblast growth factor-induced translocation of p21-activated kinase to the membrane is independent of phospholipase C-gamma1 in the differentiation of PC12 cells.
• Biological properties and expression of mucins in 5-fluorouracil resistant HT29 human colon cancer cells.
• Cholangiocarcinomas arising in cirrhosis and combined hepatocellular-cholangiocellular carcinomas share apomucin profiles.
• Chromosomal clustering of muscle-expressed genes in Caenorhabditis elegans.
• Drynariae Rhizoma promotes osteoblast differentiation and mineralization in MC3T3-E1 cells through regulation of bone morphogenetic protein-2, alkaline phosphatase, type I collagen and collagenase-1.
• Elderly Women's Grief in Korea.
• Expression of MUC2, MUC5AC and MUC6 apomucins in carcinoma, dysplasia and non-dysplastic epithelia of the gallbladder.
• Goblet cell-specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice.
• Identification and characterization of the MUC2 (human intestinal mucin) gene 5'-flanking region: promoter activity in cultured cells.
• Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma.
• Induction of mucin gene expression in middle ear of rats by tumor necrosis factor-alpha: potential cause for mucoid otitis media.
• Initiation of transcription of the MUC3A human intestinal mucin from a TATA-less promoter and comparison with the MUC3B amino terminus.
• MUC3 human intestinal mucin. Analysis of gene structure, the carboxyl terminus, and a novel upstream repetitive region.
• Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells.
• Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor.
• Monoclonal antibodies against partially deglycosylated colon cancer mucin that recognize Tn antigen.
• Mouse intestinal goblet cells expressing SV40 T antigen directed by the MUC2 mucin gene promoter undergo apoptosis upon migration to the villi.
• Optical design of the U7 undulator beamline at the Pohang Light Source.
• Phorbol 12-myristate 13-acetate induces alteration in mucin gene expression and biological properties of colon cancer cells.
• Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B.
• Stent-graft placement in a traumatic internal carotid-internal jugular fistula and pseudoaneurysm.
• Stereotactic aspiration of intracerebral haematoma: significance of surgical timing and haematoma volume reduction.
• Study of the aging perception.
• The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42.